PAQ Therapeutics Secures $39M in Series B Funding to Pioneer Autophagy-Based Drug Discovery

PAQ Therapeutics is proud to announce a significant milestone in its development journey with the successful closing of a $39 million funding round.

This substantial investment underscores the industry's confidence in our pioneering approach to restoring health and curing disease through the body’s natural autophagy mechanism.

As a biotechnology leader, PAQ Therapeutics is dedicated to revolutionizing the field of drug discovery by harnessing its proprietary ATTEC (autophagosome-tethering compound) technology.

This innovative platform is designed to transform the way small molecule degraders interact with a diverse array of cellular substrates, ranging from proteins and aggregates to lipids, organelles, and even pathogens.

The newly raised funds will accelerate research and development initiatives aimed at optimizing our ATTEC technology and advancing our pipeline of degradation therapies into clinical trials.

The investment comes at a crucial time as PAQ Therapeutics continues to push boundaries and disrupt traditional therapeutic paradigms in the biotech sector.

By leveraging the body’s intrinsic autophagy processes—as opposed to conventional inhibition or binding strategies—our groundbreaking approach offers significant potential to treat conditions that have long been considered challenging or incurable.

This funding not only bolsters our ongoing research but also reinforces our commitment to developing innovative solutions with the potential to fundamentally transform patient care and healthcare outcomes.

As we embark on this exciting chapter, PAQ Therapeutics remains dedicated to pioneering new frontiers in medicine, ensuring that our scientific advancements translate into tangible benefits for patients worldwide.